Professor of Oncology and Professor of Pharmacology
Oncology
Dr. Matthew P. Goetz, MD
|
|
Give Review
Matthew Goetz is an expert in the field of Oncology. He researched medicine at University of North Dakota School of Medicine and Health Sciences. Matthew P. Goetz is a published physician. He has 84 publications published. The most current publication "Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action."
Publications
- Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation.
- Gene Expression Profiling Identifies Responsive Patients with Cancer of Unknown Primary Treated with Carboplatin, Paclitaxel, and Everolimus: NCCTG N0871 (Alliance).
- Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen.
- Landscape of Neoadjuvant Therapy for Breast Cancer.
- TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative Systemic therapy in human epidermal growth factor receptor 2-negative primary operab...
- A polygenic risk score for breast Cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2.
- Pregnancy-associated plasma protein-A expression in human breast Cancer.
- Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies.
- Once-Daily Radiation Therapy for Inflammatory Breast Cancer.
- Comparative Uterotrophic Effects of Endoxifen and Tamoxifen in Ovariectomized Sprague-Dawley Rats.
- UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine.
- CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations.
- Androgen Receptor-Positive Triple Negative Breast Cancer: A Unique Breast Cancer Subtype.
- Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention.
- Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Recep...
- A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast Cancer.
- TSPYL5 SNPs: Association with Plasma Estradiol Concentrations and Aromatase Expression.
- Update on CYP2D6 and Tamoxifen.
- Percutaneous image-guided cryoablation of painful metastases involving bone: Multicenter trial.
- Endoxifen's Molecular Mechanisms of Action Are Concentration Dependent and Different than That of Other Anti-Estrogens.
- Matrix detachment and proteasomal inhibitors diminish Sulf-2 expression in breast Cancer cell lines and mouse xenografts.
- CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8.
- Gemcitabine and Irinotecan as First-Line Therapy for Carcinoma of Unknown Primary: Results of a Multicenter Phase II Trial.
- Automated discovery of drug treatment patterns for endocrine therapy of breast Cancer within an electronic medical record.
- Development, characterization and applications of a novel estrogen receptor beta monoclonal antibody.
- CYP2D6 and Tamoxifen: Awaiting the Denouement.
- SULT1A1, CYP2C19 and disease-free survival in early breast Cancer patients receiving tamoxifen.
- Breast Medical Oncologists' Use of Standard Prognostic Factors to Predict a 21-Gene Recurrence Score.
- Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast Cancer chemoprevention: results from the NSABP P1 and P2 clinical trials.
- Palliation of painful metastatic Disease involving bone with imaging-guided treatment: comparison of patients' immediate response to radiofrequency ablation and cryoab...
- Colonic polyposis and neoplasia in cowden Syndrome.
- Estrogen receptor-beta sensitizes breast Cancer cells to the anti-estrogenic actions of endoxifen.
- Oncophenotypic review and clinical correlates of phosphatase and tensin homolog on chromosome 10 hamartoma tumor Syndrome.
- Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
- Update on CYP2D6 and its impact on tamoxifen therapy.
- Coprescription of tamoxifen and medications that inhibit CYP2D6.
- Variation in anastrozole metabolism and pharmacodynamics in women with early breast Cancer.
- Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast Cancer.
- Tamoxifen, endoxifen, and CYP2D6: the rules for evaluating a predictive factor.
- Association between CYP2D6 polymorphisms and outcomes among women with early stage breast Cancer treated with tamoxifen.
- Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging.
- The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast Cancer cells.
- Endocrine therapy in 2009: consideration of the tumor and the Host.
- If you hold it off-hours, will they come? Results from a feasibility project intended to stimulate interest in the physician-investigator career path among medical onc...
- Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance.
- Molecular Analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy.
- Early discontinuation of tamoxifen: a lesson for oncologists.
- A multidisciplinary approach to the management of breast Cancer, part 2: therapeutic considerations.
- A multidisciplinary approach to the management of breast Cancer, part 1: prevention and diagnosis.
- Pemetrexed and oxaliplatin for metastatic colorectal Cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248.
- Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal Cancer.
- Gene-expression-based predictors for breast Cancer.
- Painful metastases involving bone: percutaneous image-guided cryoablation--prospective trial interim Analysis.
- Hand-foot syndrome after dose-dense adjuvant chemotherapy for breast Cancer: a case series.
- A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen.
- Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.
- Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced Cancer.
- Oxaliplatin plus oral fluoropyrimidines in colorectal Cancer.
- Primer on medical genomics. Part XII: Pharmacogenomics--general principles with Cancer as a model.
- Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study.
- A hot flash on tamoxifen metabolism.
- Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid Tumors.
- Painful metastases involving bone: feasibility of percutaneous CT- and US-guided radio-frequency ablation.
- ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast Cancer.
- The effects of a novel hormonal breast Cancer therapy, endoxifen, on the mouse skeleton.
- Imaging techniques in inflammatory bowel Disease: recent trends, questions and answers.
- Molecular Analysis of two cytochrome P450 monooxygenase genes required for paxilline biosynthesis in Penicillium paxilli, and effects of paxilline intermediates on mam...
- Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action.
- Recognition and characterization of small colonic neoplasia with high-definition colonoscopy using i-Scan is as precise as chromoendoscopy.
- Mayo Clinic office visit. Increase in mastectomies. An interview with Matthew Goetz, M.D.
- High definition colonoscopy combined with i-Scan is superior in the detection of coloRectal neoplasias compared with standard video colonoscopy: a prospective randomiz...
- Targeted Therapy for BRCA2 Deficient Tumors.
- The Hsp90 chaperone complex as a novel target for Cancer therapy.
- Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.
- Developments in combination chemotherapy for colorectal Cancer.
- Image-guided ablation of painful metastatic bone Tumors: a new and effective approach to a difficult problem.
- Clinical trial designs for prospective validation of biomarkers.
- CYP2D6 genotype and tamoxifen response.
- Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast Cancer...
- The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
- Aromatase inhibitors and tamoxifen: where do we go from here?
- Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast Cancer cells.
- Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism.
Schools
University Of North Dakota School Of Medicine
University Of Michigan
Mayo Clinic Rochester
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Mayo School of Graduate Medical Education -
University of Michigan Hospitals and Health Centers -
University of North Dakota School of Medicine and Health Sciences
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1255310611 | |
| NPPES Provider LastName | GOETZ | |
| NPPES Provider FirstName | MATTHEW | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 164.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1255310611 |
| Last Name Of The Provider | GOETZ |
| First Name Of The Provider | MATTHEW |
| View All |
Similar Doctors
|
|
Dr. Aminah Jatoi, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patrick A. Burch, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen Frytak, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Alla Keyzner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sameer A. Parikh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michaela S. Banck, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Martha Q. Lacy, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Prema P. Peethambaram, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dennis A. Gastineau, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert J. Hoyer, MD |
|
|
Dr. Kristin C. Francis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brian D. Koh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shakila P. Khan, MD |
|
|
Dr. Samith T. Kochuparambil, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen J. Russell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rahma M. Warsame, MD
This Doctor is OpenDoctor Recommended.
|